Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology & Vascular Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD93 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD93 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD93 Products |
| Gene Delivery | CD93 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD93 Products |
| Benchmark Ab | Anti-CD93 (Sequence of PMC-122) Recombinant positive control. |
View CD93 Products |
| Validator | CD93 siRNA Set For knockdown verification. |
View CD93 Products |
| Related Target A | VEGFR2 Synergistic pathway in tumor angiogenesis and endothelial cell activation. |
View VEGFR2 Products |
| Related Target B | CLEC14A Tumor endothelial marker regulating angiogenesis and vascular integrity. |
View CLEC14A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Translation (Cyno/Mouse vs Human) | Human, Mouse, and Cynomolgus CD93 ortholog proteins available with >95% purity |
| Shedding & Soluble CD93 (sCD93) Interference | ECD domain-specific constructs designed to differentiate membrane-bound vs. cleaved CD93 |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD93 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD93 therapeutics is intensifying, with major players shifting focus from traditional anti-angiogenesis agents to vascular normalization and tumor microenvironment (TME) reprogramming. As first-generation therapies reach the clinic, the next wave of R&D is targeting CD93 to reverse immunosuppression and enhance the infiltration of immune effector cells into solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | PharmAbcine | Glioblastoma, Solid Tumors | Blocking Assay (Need high-purity, native-glycosylated ECD-Fc) |
| CAR-T / Cell Therapy | Academic Institutions | Acute Myeloid Leukemia (AML) | Target Expression & Cytotoxicity (Need Lentivirus for stable cell lines) |
| Bispecific Antibody | Biotech Startups | Refractory Solid Tumors | Dual-Target Binding (Need purified CD93 and VEGFR2/PD-L1 proteins) |